HANSOH PHARMA (03692.HK): NMPA Accepts NDA for HS-20093, Its B7-H3-Targeting ADC, in Osteosarcoma

NewTimeSpace News: On 24 September 2026, Hansoh Pharmaceutical Group Company Limited (the "Company") voluntarily announced that the board was pleased to announce that, on 24 September 2026, the marketing licence application for the Group's innovative drug HS-20093 for injection was accepted by the National Medical Products Administration (NMPA) of China for the treatment of osteosarcoma patients aged 12 years or older who have failed at least two prior lines of therapy.

The announcement stated that HS-20093 for injection is a B7-H3-targeting antibody-drug conjugate (ADC) independently developed by the Group. The announcement was signed by Madam Zhong Huijuan, chairman of the Group, and issued in Hong Kong.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.